news
FDA approves Novartis’ Cosentyx for AS and PsA
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
List view / Grid view
Cosentyx (secukinumab)
Cosentyx (secukinumab) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A,[1] and is manufactured by Novartis Pharma AG for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.
It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning. On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis. On January 15, 2016, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with ankylosing spondylitis, and psoriatic arthritis.
news
Novartis’ secukinumab gains two landmark EU approvals
23 November 2015 | By Victoria White
The EC has approved secukinumab (Costenyx) for the treatment of people living with ankylosing spondylitis and psoriatic arthritis...
news
CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
news
Cosentyx demonstrates sustained efficacy in plaque psoriasis
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
news
J&J and Norvatis to fight it out in the axSpA treatment space
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
news
Axial spondyloarthritis treatment market value will almost double by 2024
11 June 2015 | By Victoria White
The global market value for axial spondyloarthritis therapeutics will expand from $1.5 billion in 2014 to reach $2.9 billion by 2024...
news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
news
Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin
13 March 2015 | By Novartis
Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology...
